Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd

Blood (2025) 146 (Supplement 1): 87.

https://doi.org/10.1182/blood-2025-87

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Blood (2025) 146 (Supplement 1): 86.

https://doi.org/10.1182/blood-2025-86

Published: 2025

Journal Articles

A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis.

Amy Burd, Brian Ledwith, Megan Johnstone, Erin Hertlein, Alexander Khvat, Ola Elgamal, Ruben Karapetian, Kate Dokukina, Fraser Pickersgill, Peter Schrader, Nikolay Savchuk, Iain Dukes, John Byrd

Blood (2025) 146 (Supplement 1): 5067.

https://doi.org/10.1182/blood-2025-5067

Published: 2025

Journal Articles

A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)

John Byrd, Brian Ledwith, Fraser Pickersgill, Kate Dokukina, Ruben Karapetian, Chia Sharpe, Erin Hertlein, Megan Johnstone, Alexei Pushechnikov, Christopher Argent, Nikolay Savchuk, Iain Dukes, Amy Burd

Blood (2025) 146 (Supplement 1): 6819.

https://doi.org/10.1182/blood-2025-6819

Published: 2025

Journal Articles

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

Blood (2025) 146 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2025-6781

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Systematic molecular profiling to identify determinants of response to ibrutinib

Blood (2025) 146 (Supplement 1): 3881.

https://doi.org/10.1182/blood-2025-3881

Published: 2025

Journal Articles

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Blood (2025) 146 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2025-1723

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Blood (2025) 146 (Supplement 1): 220.

https://doi.org/10.1182/blood-2025-220

Published: 2025

Journal Articles

ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases

Shailaja Hegde, Alexander Khvat, Ruben Karapetian, Brian Ledwith, Fraser Pickersgill, Megan Johnstone, Eric Vick, Emily Curran, Iain Dukes, Amy Burd, Nikolay Savchuk, Vladislav Parchincky, Igor Rezekin, Erin Hertlein, John Byrd

Blood (2025) 146 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2025-1988

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Journal Articles

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Don Benson, Leslie Andritsos, Mehdi Hamadani, Thomas Lin, Joseph Flynn, Jeffrey Jones, William Blum, MD, Patrick Elder, Gerard Lozanski, John Byrd, Steven Devine

Blood (2008) 112 (11): 3300.

https://doi.org/10.1182/blood.V112.11.3300.3300

Published: 2008

Journal Articles

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Nuzhat I. Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina, John Byrd

Blood (2008) 111 (3): 1594–1602.

https://doi.org/10.1182/blood-2007-03-082024

Published: 2008

Journal Articles

Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS.

Sheng Wei, MD, Kathy Rocha, BS, Ann Williams, Ph.D., Xianhong Chen, Ph.D, P.K. Burnette, Ph.D., Julie Y. Djeu, Ph.D., Qing Liu, Ph.D., John Byrd, M.D., Lubomir Sokol, M.D., Nick Lawrence, Ph.D., Roberta Pireddu, Ph.D, Gordon Dewald, Ph.D., Jaroslaw Maciejewski, M.D., Alan List, M.D.

Blood (2007) 110 (11): 118.

https://doi.org/10.1182/blood.V110.11.118.118

Published: 2007

Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD

Blood (2006) 108 (11): 35.

https://doi.org/10.1182/blood.V108.11.35.35

Published: 2006

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis.

A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Systematic molecular profiling to identify determinants of response to ibrutinib

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS.

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only